| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Biacetyl monoxime targets myosin ATPase, the enzyme responsible for ATP hydrolysis in muscle contraction. By inhibiting myosin ATPase, the compound blocks the interaction between actin and myosin, preventing muscle contraction. It is a reversible inhibitor of myosin ATPase. The compound also chemically removes phosphate groups from many proteins and has been used to study DRK1 channels expressed in Xenopus oocytes. It is used as a reagent for the colorimetric determination of urea.
|
|---|---|
| ln Vitro |
In both 6 and 48 hours, Diacetone monoxime (50 mM) decreases C's cellulase secretion. cinerea [1]. Endoplasmic reticulum localization is not affected by diethyl monoxime (50 mM, 2 and 4 hours), although the Golgi apparatus is [1]. Without the use of efflux inhibitors, dialethylmonoxime (0–30 mM) causes the concentration-dependent release of SR Ca2+, which is maximally reduced by 72% at pCa 6.0 [2]. Diacetyl monoxime functions as a chemical phosphatase, which has led to theories that its contraction-inhibiting effect may be due to the dephosphorylation of important Ca2+ channel proteins [2]. Neither myosin-V nor myosin-VI, the two distinct myosin-I isoforms, had their ATPase activity inhibited by dialetyl monoxime [3]. In isolated single cardiomyocytes from SHR and WKY rats, diethyl monooxime (0–50 mM) suppresses L-type Ca2+ currents [4]. In cultured newborn rat cardiomyocytes, dialetyl monooxime dramatically shortens the length of both electrically triggered and spontaneous action potentials [4].
Biacetyl monoxime is a myosin ATPase inhibitor that blocks skeletal and cardiac muscle contraction. It acts by inhibiting the ATPase activity of myosin, preventing the cross-bridge cycle and muscle contraction. The compound also chemically removes phosphate groups from many proteins. It is used as a reagent for the colorimetric determination of urea. The compound has been used in studies of DRK1 channels expressed in Xenopus oocytes. |
| ln Vivo |
Hypotensive effects can be caused by intravenous injection of dialetyl monoxime (0-200 mg/kg) once [4]. Picrotoxin-induced convulsions can be treated with diacetyl monoxime (0-205 mg/kg; intraperitoneal injection; once) to prevent convulsions [5].
In vivo, biacetyl monoxime is used as a skeletal and cardiac muscle contraction inhibitor. It has been studied for its effects on muscle contractility in various experimental models. The compound's inhibition of myosin ATPase leads to reduced muscle force generation. It is used in research to study muscle physiology and contractile mechanisms. The compound is not used as a therapeutic agent but is a valuable research tool for studying muscle contraction and ATPase activity. |
| Enzyme Assay |
The in vitro enzyme assay for biacetyl monoxime typically involves measuring the inhibition of myosin ATPase activity. Myosin is incubated with varying concentrations of biacetyl monoxime (typically 0.1-100 mM) in the presence of ATP. The enzymatic activity is measured by monitoring the release of inorganic phosphate using colorimetric assays such as the Malachite Green or Fiske-SubbaRow method. The IC50 value is determined by plotting the percentage of inhibition against compound concentration. The compound is dissolved in water or buffer.
|
| Cell Assay |
In vitro cellular assays for biacetyl monoxime typically involve treating muscle cells or cardiomyocytes with the compound at concentrations ranging from 0.1 to 50 mM. Muscle contraction is assessed by measuring cell shortening or calcium transients. Cell viability is assessed using MTT or other standard assays. The compound is dissolved in water or DMSO as a stock solution and diluted in cell culture medium. The compound's effects on myosin ATPase activity and muscle contraction are assessed in these assays.
|
| Animal Protocol |
Animal/Disease Models: Male SHR and age-matched WKY rats [4]
Doses: 5, 30, 100 and 200 mg/kg Route of Administration: intravenous (iv) (iv)administration, 1 mL/kg, once Experimental Results: Arterial blood pressure of both strains were the same By lowering the SHR, the response speed is Dramatically improved. Animal/Disease Models: Male mice (20 to 25 g) [5] Doses: 51, 103 and 205 mg/kg combined with intraperitoneal (ip) injection of 3.0 mg/kg Picrotoxin Route of Administration: one intraperitoneal (ip) injection Experimental Results: demonstrated dose-dependent resistance Convulsions caused by picrotoxins. In vivo animal studies for biacetyl monoxime typically involve administration to rodents via intravenous or intraperitoneal injection at doses determined from preliminary studies. Muscle contractility is assessed by measuring force generation in isolated muscle preparations or by echocardiography in live animals. The compound's effects on cardiac and skeletal muscle function are evaluated. Blood and tissue samples are collected for pharmacokinetic analysis. The compound is formulated in appropriate vehicles for administration. |
| ADME/Pharmacokinetics |
Biacetyl monoxime has a molecular weight of 101.10 g/mol and formula C4H7NO2. It is very soluble in water and has a melting point of 75.0-77.0°C. Purity is >98.0%. The compound appears as a cream-colored powder. Recommended storage is at room temperature in a dry place. Detailed PK parameters such as half-life, Cmax, AUC, and bioavailability would require experimental determination. The compound is soluble in water and other polar solvents.
|
| Toxicity/Toxicokinetics |
Biacetyl monoxime is intended for research use only and is not approved for human therapeutic applications. The compound is a myosin ATPase inhibitor and may have toxic effects at high concentrations. Appropriate safety precautions should be taken when handling, including wearing gloves and protective eyewear. The compound should not be inhaled, swallowed, or allowed to contact skin and eyes. Standard toxicity assessments would include acute toxicity, genotoxicity, and repeated-dose toxicity studies.
|
| References |
|
| Additional Infomation |
2,3-Butanedione oxime is a milky white powder. (NTP, 1992)
Diacetyl monooxime is a ketooxime formed by the condensation of butane-2,3-dione with hydroxylamine. It is a reversible myosin ATPase inhibitor. It can be used as a cholinesterase reactivator, chromogenic agent, and EC 3.6.1.3 (adenosine triphosphatase) inhibitor. Biacetyl monoxime (CAS 57-71-6), also known as 2,3-butanedione monoxime (BDM) or diacetyl monoxime, is a myosin ATPase inhibitor and muscle contraction inhibitor. It has a molecular weight of 101.10 g/mol and formula C4H7NO2. The compound is very soluble in water and has a melting point of 75.0-77.0°C. It is used as a reagent for the colorimetric determination of urea. The compound is also known as diacetyl monooxime and Isonitrosoethyl methyl ketone. |
| Molecular Formula |
C4H7NO2
|
|---|---|
| Molecular Weight |
101.1039
|
| Exact Mass |
101.047
|
| CAS # |
57-71-6
|
| PubChem CID |
6409633
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
185.5±9.0 °C at 760 mmHg
|
| Melting Point |
75-78 °C(lit.)
|
| Flash Point |
66.0±18.7 °C
|
| Vapour Pressure |
0.3±0.7 mmHg at 25°C
|
| Index of Refraction |
1.452
|
| LogP |
-0.47
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
7
|
| Complexity |
106
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C/C(=N\O)/C(=O)C
|
| InChi Key |
FSEUPUDHEBLWJY-HWKANZROSA-N
|
| InChi Code |
InChI=1S/C4H7NO2/c1-3(5-7)4(2)6/h7H,1-2H3/b5-3+
|
| Chemical Name |
(3E)-3-hydroxyiminobutan-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~989.12 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (20.57 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (20.57 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (20.57 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 9.8912 mL | 49.4560 mL | 98.9120 mL | |
| 5 mM | 1.9782 mL | 9.8912 mL | 19.7824 mL | |
| 10 mM | 0.9891 mL | 4.9456 mL | 9.8912 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
